Datapoint: Regence Sees 95% Biosimilar Adoption

Regence, the parent company of four Blues affiliates in Idaho, Oregon, Utah and Washington, last week said it has reduced specialty drug spend by $37 million after transitioning to the use of biosimilars. The company said it currently has a 95% adoption rate of biosimilars among its health plan members, and it expects costs to further decrease as more biosimilars become available in 2023. Regence’s four MCOs currently enroll 2,012,243 people in primary medical coverage, with 39.0% enrolled in risk-based commercial plans, and 54.4% in non-risk ASO plans.

Source: AIS’s Directory of Health Plans

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today